1. Home
  2. SPRO vs BOF Comparison

SPRO vs BOF Comparison

Compare SPRO & BOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.20

Market Cap

71.6M

Sector

Health Care

ML Signal

N/A

Logo BranchOut Food Inc.

BOF

BranchOut Food Inc.

N/A

Current Price

$3.98

Market Cap

63.6M

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
BOF
Founded
2013
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Packaged Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
71.6M
63.6M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
SPRO
BOF
Price
$1.20
$3.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.5M
21.0K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
31.33
EPS
N/A
N/A
Revenue
$66,802,000.00
$3,184,018.00
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
258.20
52 Week Low
$1.08
$1.93
52 Week High
$3.08
$5.25

Technical Indicators

Market Signals
Indicator
SPRO
BOF
Relative Strength Index (RSI) 31.16 44.61
Support Level $1.10 $2.86
Resistance Level $1.28 $4.29
Average True Range (ATR) 0.06 0.24
MACD 0.04 -0.01
Stochastic Oscillator 40.00 16.69

Price Performance

Historical Comparison
SPRO
BOF

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About BOF BranchOut Food Inc.

Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients. The products are mainly sold through three channels: branded retail snack products, private label products for retailers, and fruit and vegetable ingredients sold to food manufacturers.

Share on Social Networks: